October 1, 2013 I The global tumor profiling market is anticipated to reach $35.03 billion by 2018 growing at a CAGR of 18.50%. The market is divided by geography (North America, Europe, Asia-Pacific, and Rest of the World), applications (Personalized Medicine, Diagnostics, Biomarker Discovery, Prognosis, and Research Applications), technologies (Next-Generation Sequencing, Quantitative PCR, Immunohistochemistry, FISH/CISH, and Microarray) and segments (Genomics, Proteomics, Metabolomics, and Epigenetics). Further, each application, technology, and segment type is broken down by geography, with an exhaustive revenue analysis for the entire forecast period. Of the above mentioned applications, Personalized Medicine is the largest revenue sector and will be the fastest-growing segment.
This research results can be found in the new report “Cancer/Tumor Profiling Market [Applications (Personalized Medicine, Diagnostics, Biomarker Discovery, Prognosis, Research), Technologies (NGS, QPCR, IHC, FISH/CISH, Microarray), Segments: Genomics, Proteomics, Metabolomics, Epigenetics)] 2013 – 2018” at http://pipelinereview.com/index.php/product-category/market-business/cancer-tumor-profiling-market-applications-personalized-medicine-diagnostics-biomarker-discovery-prognosis-research-technologies-ngs-qpcr-ihc-fish-cish-microarray-segments-genomics-proteomics–detail
The cancer profiling market is driven mainly by the rising number of cancer cases. Technological advancements to identify the exact cause of the condition are considered as the second major driver. Additionally, demand for safer and cost-effective treatment further drives the market. The rapid growth of the tumor profiling market is attributed to its promising application in personalized cancer therapy; and its extension in early diagnosis, disease prognosis, and research applications will further enhance its market growth. The current approach of cancer profiling in targeted therapy and personalized medicine for cancer has the potential to address the current demands and fill the gaps in the healthcare industry.
North America is a significant contributor to the market, followed by Europe, due to the presence of technology providers and better R&D facilities. The new markets that are expected to grow at a brisk pace are emerging economics such as China, India, Japan, and other regions of Asia-Pacific and the untapped markets of Europe due to their growing GDP, healthcare costs, and rising demand for safe and cost-effective diagnostics and therapeutics.
Key players in cancer profiling market are Boreal Genomics Inc. (U.S.), Caris Life Sciences (U.S.), Genomic Health Inc. (U.S.), Illumina, Inc. (U.S.), Life Technologies Corporation (U.S.), NeoGenomics Laboratories (U.S.), Oxford Gene Technology Ltd. (U.K.), Precision Therapeutics Inc. (U.S.), bioTheranostics (U.S.), Proteome Sciences PLC (U.K.), Agendia (The Netherlands), Nanostring Technologies (U.S.), Rational Therapeutics (U.S.), Oncopath Laboratories (U.S.), and RiboMed Biotechnologies Inc. (U.S.).
SOURCE: MarketsandMarkets.com
Post Views: 150
October 1, 2013 I The global tumor profiling market is anticipated to reach $35.03 billion by 2018 growing at a CAGR of 18.50%. The market is divided by geography (North America, Europe, Asia-Pacific, and Rest of the World), applications (Personalized Medicine, Diagnostics, Biomarker Discovery, Prognosis, and Research Applications), technologies (Next-Generation Sequencing, Quantitative PCR, Immunohistochemistry, FISH/CISH, and Microarray) and segments (Genomics, Proteomics, Metabolomics, and Epigenetics). Further, each application, technology, and segment type is broken down by geography, with an exhaustive revenue analysis for the entire forecast period. Of the above mentioned applications, Personalized Medicine is the largest revenue sector and will be the fastest-growing segment.
This research results can be found in the new report “Cancer/Tumor Profiling Market [Applications (Personalized Medicine, Diagnostics, Biomarker Discovery, Prognosis, Research), Technologies (NGS, QPCR, IHC, FISH/CISH, Microarray), Segments: Genomics, Proteomics, Metabolomics, Epigenetics)] 2013 – 2018” at http://pipelinereview.com/index.php/product-category/market-business/cancer-tumor-profiling-market-applications-personalized-medicine-diagnostics-biomarker-discovery-prognosis-research-technologies-ngs-qpcr-ihc-fish-cish-microarray-segments-genomics-proteomics–detail
The cancer profiling market is driven mainly by the rising number of cancer cases. Technological advancements to identify the exact cause of the condition are considered as the second major driver. Additionally, demand for safer and cost-effective treatment further drives the market. The rapid growth of the tumor profiling market is attributed to its promising application in personalized cancer therapy; and its extension in early diagnosis, disease prognosis, and research applications will further enhance its market growth. The current approach of cancer profiling in targeted therapy and personalized medicine for cancer has the potential to address the current demands and fill the gaps in the healthcare industry.
North America is a significant contributor to the market, followed by Europe, due to the presence of technology providers and better R&D facilities. The new markets that are expected to grow at a brisk pace are emerging economics such as China, India, Japan, and other regions of Asia-Pacific and the untapped markets of Europe due to their growing GDP, healthcare costs, and rising demand for safe and cost-effective diagnostics and therapeutics.
Key players in cancer profiling market are Boreal Genomics Inc. (U.S.), Caris Life Sciences (U.S.), Genomic Health Inc. (U.S.), Illumina, Inc. (U.S.), Life Technologies Corporation (U.S.), NeoGenomics Laboratories (U.S.), Oxford Gene Technology Ltd. (U.K.), Precision Therapeutics Inc. (U.S.), bioTheranostics (U.S.), Proteome Sciences PLC (U.K.), Agendia (The Netherlands), Nanostring Technologies (U.S.), Rational Therapeutics (U.S.), Oncopath Laboratories (U.S.), and RiboMed Biotechnologies Inc. (U.S.).
SOURCE: MarketsandMarkets.com
Post Views: 150
